Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
December 31, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Over 21,000 migraine attacks treated with AXS-07 Achieved migraine pain relief in approximately 70% of patients, and pain freedom in approximately 40% of patients, at 2 hours Achieved...
INTERCEPT PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Intercept Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
November 05, 2020 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United...
Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine
April 06, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Achieved freedom from migraine pain in 33% of AXS-07 patients versus 16% for placebo at 2 hours (co-primary endpoint, p=0.002) Prevented progression of migraine pain beyond mild intensity in 74% of...
Axsome Therapeutics to Report Third Quarter 2019 Financial Results on November 7, 2019
October 29, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, November 7, 2019 at 8:00 AM Eastern Time NEW YORK, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine
October 28, 2019 07:05 ET
|
Axsome Therapeutics, Inc.
Majority of physicians indicate improved efficacy is most significant unmet need in the acute treatment of migraine Majority of physicians would be more likely to prescribe AXS-07 over current and...
Axsome Therapeutics Announces Continued Progress in Clinical Development of AXS-07 for the Acute Treatment of Migraine
October 28, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Enrollment in MOMENTUM Phase 3 migraine trial of AXS-07 in patients with history of inadequate response nearly complete; on track for topline results in 4Q 2019 First patient dosed in new INTERCEPT...
Aerojet Rocketdyne's Propulsion Supported 11th Successful Missile Defense Intercept for GMD
March 27, 2019 11:23 ET
|
Aerojet Rocketdyne, Inc.
Divert and Attitude Control System on Raytheon Exoatmospheric Kill Vehicle (EKV) successfully performed its mission-critical roleFirst salvo test for the GMD programFlight test further demonstrated...
Comstock Mining Reports High-Grade Intercepts From Initial Drilling
February 26, 2015 08:01 ET
|
Comstock Mining Inc.
VIRGINIA CITY, NV--(Marketwired - February 26, 2015) - Comstock Mining Inc. (the 'Company') (NYSE MKT: LODE) announced that the drill program commencing on the Eastside of the Lucerne continues to...
Narus Receives a 2009 INTERNET TELEPHONY Excellence Award
November 17, 2009 14:08 ET
|
Narus
SUNNYVALE, CA--(Marketwire - November 17, 2009) - Narus, Inc. announced today that Technology Marketing Corporation (TMC)
has named NarusInsight as a recipient of the 2009 INTERNET...
Narus to Host Session on Cyber Security at SUPERCOMM 2009
October 20, 2009 07:53 ET
|
Narus
SUNNYDALE, CA--(Marketwire - October 20, 2009) -
WHAT:
Narus, Inc., the
leader in
real-time traffic intelligence, announced today that it will
participate in SUPERCOMM 2009 with a presentation...